Compare PRAA & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PRAA | SLBT |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Taiwan |
| Employees | 170 | 20 |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 710.0M | 846.7M |
| IPO Year | 2002 | 2025 |
| Metric | PRAA | SLBT |
|---|---|---|
| Price | $20.27 | $1.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 444.7K | 84.0K |
| Earning Date | 11-02-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.24 | N/A |
| Revenue | ★ $1,201,837,000.00 | N/A |
| Revenue This Year | $8.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.91 | ★ N/A |
| Revenue Growth | ★ 7.83 | N/A |
| 52 Week Low | $10.25 | $1.42 |
| 52 Week High | $22.55 | $6.25 |
| Indicator | PRAA | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 32.89 |
| Support Level | $18.32 | $1.42 |
| Resistance Level | $21.39 | $1.98 |
| Average True Range (ATR) | 0.89 | 0.14 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 70.95 | 15.32 |
PRA Group Inc is a specialty finance company engaged in the purchase, collection, and management of nonperforming loan portfolios. The majority of the loans it purchases are from credit originators who have chosen not to pursue, or have been unsuccessful in collecting, the full balance owed to them (Core accounts). To a lesser extent, the company also purchases loans in situations where the customer is involved in a bankruptcy or similar proceeding (Insolvency accounts). As part of an ancillary business, it also purchases and provides fee-based services for class action claims recoveries in the U.S. The company has two operating and reportable segments, comprised of its U.S. and European businesses. The majority of its revenue is generated from the United States.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.